Advertisement

AAPS PharmSciTech

, Volume 19, Issue 5, pp 2407–2417 | Cite as

Investigating the Physicochemical Stability of Highly Purified Darunavir Ethanolate Extracted from PREZISTA® Tablets

  • Haichen Nie
  • Huaping Mo
  • Stephen R. Byrn
Research Article

Abstract

Understanding physicochemical stability of darunavir ethanolate is expected to be of critical importance for the development and manufacturing of high-quality darunavir-related pharmaceutical products. However, there are no enabling monographs for darunavir to illustrate its solid-state chemistry, impurity profile, and assay methods. In addition, the US Pharmacopeia reference standard of darunavir is still not commercially available. It has been also challenging to find reliable vendors to obtain highly purified darunavir ethanolate crystals to conduct the physicochemical stability testing. In the present research, we developed a straightforward and cost-effective approach to extract and purify darunavir ethanolate from PREZISTA® tablets using reverse-engineering and crystallization. Using these highly purified crystals, we thoroughly evaluated the potential risks of degradation and form conversions of darunavir ethanolate at stressed conditions to define the manufacturing and packaging specifications for darunavir-related products. Amorphization was observed under thermal storage caused by desolvation of darunavir ethanolate. The ethanolate-to-hydrate conversion of darunavir was observed at high relative humidity conditions. Moreover, acid/base-induced degradations of darunavir have been investigated herein to determine the possible drug-excipient compatibility issues in formulations. Furthermore, it is of particular interests to allow the production of high-quality darunavir-ritonavir fixed dose combinations for marketing in Africa. Thus, a validated HPLC method was developed according to ICH guideline to simultaneously quantify assays of darunavir and ritonavir in a single injection. In summary, the findings of this study provide important information for pharmaceutical scientists to design and develop reliable formulations and processings for darunavir-related products with improved stability.

KEY WORDS

darunavir ethanolate darunavir hydrate desolvation form conversion darunvair ritonavir combination 

Notes

Acknowledgements

The authors would like to thank global fellowship program of United States Pharmacopeial Convention (USP) for supporting this research. Shankari Shivaprasad from USP is thanked for helpful scientific discussions. Dr. Ke Fang is acknowledged for helping with the HPLC method development.

Funding information

This research received funding from global fellowship program of United States Pharmacopeia Convention (USP).

Supplementary material

12249_2018_1036_MOESM1_ESM.pdf (288 kb)
ESM 1 (PDF 288 kb)

References

  1. 1.
    Mitsuya H, Maeda K, Das D, Ghosh AK. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Advances in Pharmacology: Academic Press; 2008. p. 169–97.Google Scholar
  2. 2.
    Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science. 1990;249(4976):1533–44.  https://doi.org/10.1126/science.1699273.CrossRefPubMedGoogle Scholar
  3. 3.
    Ghosh AK, Chapsal BD, Weber IT, Mitsuya H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc Chem Res. 2008;41(1):78–86.  https://doi.org/10.1021/ar7001232.CrossRefPubMedGoogle Scholar
  4. 4.
    Ghosh AK, Kincaid JF, Cho W, Walters DE, Krishnan K, Hussain KA, et al. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg Med Chem Lett. 1998;8(6):687–90.  https://doi.org/10.1016/S0960-894X(98)00098-5. CrossRefPubMedGoogle Scholar
  5. 5.
    Ghosh AK, Dawson ZL, Mitsuya H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem. 2007;15(24):7576–80.  https://doi.org/10.1016/j.bmc.2007.09.010.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Quaedflieg PJLM, Kesteleyn BRR, Wigerinck PBTP, Goyvaerts NMF, Vijn RJ, Liebregts CSM, et al. Stereoselective and efficient synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol. Org Lett. 2005;7(26):5917–20.  https://doi.org/10.1021/ol052554i.CrossRefPubMedGoogle Scholar
  7. 7.
    Ghosh AK, Sridhar PR, Leshchenko S, Hussain AK, Li J, Kovalevsky AY, et al. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem. 2006;49(17):5252–61.  https://doi.org/10.1021/jm060561m.CrossRefPubMedGoogle Scholar
  8. 8.
    Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem. 2007;282(39):28709–20.  https://doi.org/10.1074/jbc.M703938200.CrossRefPubMedGoogle Scholar
  9. 9.
    McCoy C. Darunavir: a nonpeptidic antiretroviral protease inhibitor. Clin Ther. 2007;29(8):1559–76.  https://doi.org/10.1016/j.clinthera.2007.08.016. CrossRefPubMedGoogle Scholar
  10. 10.
    De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314–21.  https://doi.org/10.1128/aac.49.6.2314-2321.2005.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Martinez-Cajas JL, Wainberg MA. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antivir Res. 2007;76(3):203–21.  https://doi.org/10.1016/j.antiviral.2007.06.010. CrossRefPubMedGoogle Scholar
  12. 12.
    Neely M, Kovacs A. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. Ther Clin Risk Manag. 2009;5:595–615.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Van Gyseghem E, Stokbroekx S, de Armas HN, Dickens J, Vanstockem M, Baert L, et al. Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci. 2009;38(5):489–97.  https://doi.org/10.1016/j.ejps.2009.09.013. CrossRefPubMedGoogle Scholar
  14. 14.
    Vermeersch HWP, Thone DJC, Janssens LDM-L. US7700645 (B2) - Pseudopolymorphic forms of a HIV protease inhibitor. Tibotec Pharmaceuticals Ltd 2010.Google Scholar
  15. 15.
    Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res 1995;12(7):945–954. doi:  https://doi.org/10.1023/a:1016241927429.
  16. 16.
    Byrn SR, Zografi G, Chen X. Solvates and hydrates. Solid state properties of pharmaceutical materials: John Wiley & Sons, Inc.; 2017. p. 38–47.Google Scholar
  17. 17.
    Threlfall TL. Analysis of organic polymorphs. A review. Analyst. 1995;120(10):2435–60.  https://doi.org/10.1039/an9952002435.CrossRefGoogle Scholar
  18. 18.
    Kobayashi Y, Ito S, Itai S, Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm. 2000;193(2):137–46.  https://doi.org/10.1016/S0378-5173(99)00315-4. CrossRefPubMedGoogle Scholar
  19. 19.
    Shefter E, Higuchi T. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J Pharm Sci. 1963;52(8):781–91.  https://doi.org/10.1002/jps.2600520815.CrossRefPubMedGoogle Scholar
  20. 20.
    Grzesiak AL, Lang M, Kim K, Matzger AJ. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci. 2003;92(11):2260–71.  https://doi.org/10.1002/jps.10455. CrossRefPubMedGoogle Scholar
  21. 21.
    Yoshihashi Y, Yonemochi E, Terada K. Estimation of initial dissolution rate of drug substance by thermal analysis: application for carbamazepine hydrate. Pharm Dev Technol. 2002;7(1):89–95.  https://doi.org/10.1081/pdt-120002234.CrossRefPubMedGoogle Scholar
  22. 22.
    Morris K. Structural aspects of hydrates and solvates. In: Brittain HG, editor. Polymorphism in pharmaceutical solids, vol. 1999. New York: Marcel Dekker. p. 125–81.Google Scholar
  23. 23.
    Fabbiani FPA, Byrne LT, McKinnon JJ, Spackman MA. Solvent inclusion in the structural voids of form II carbamazepine: single-crystal X-ray diffraction, NMR spectroscopy and Hirshfeld surface analysis. CrystEngComm. 2007;9(9):728–31.  https://doi.org/10.1039/b708303n.CrossRefGoogle Scholar
  24. 24.
    Pfeiffer RR, Yang KS, Tucker MA. Crystal pseudopolymorphism of cephaloglycin and cephalexin. J Pharm Sci. 1970;59(12):1809–14.  https://doi.org/10.1002/jps.2600591222.CrossRefPubMedGoogle Scholar
  25. 25.
    Byrn S. Loss of solvent of crystallization. In: Byrn S, Pfeiffer R, Joseph S, editors. Solid-state chemistry of drugs. West Laffayette, IN: SSCI, Inc.; 1999. p. 279–303.Google Scholar
  26. 26.
    Byrn S. Chemical transformations in solid state. In: Byrn S, Pfeiffer R, Joseph S, editors. Solid-state chemistry of drugs. West Laffayette, IN: SSCI, Inc.. 1999. p. 305–458.Google Scholar
  27. 27.
    Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clin Pharmacokinet. 1998;35(4):275–91.  https://doi.org/10.2165/00003088-199835040-00002.CrossRefPubMedGoogle Scholar
  28. 28.
    Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother. 2007;60(6):1195–205.  https://doi.org/10.1093/jac/dkm364.CrossRefPubMedGoogle Scholar
  29. 29.
    Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. The Lancet. 370(9581):49–58.  https://doi.org/10.1016/s0140-6736(07)61049-6.
  30. 30.
    ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology. 2005.Google Scholar
  31. 31.
    Nie H, Mo H, Zhang M, Song Y, Fang K, Taylor LS, et al. Investigating the interaction pattern and structural elements of a drug–polymer complex at the molecular level. Mol Pharm. 2015;12(7):2459–68.  https://doi.org/10.1021/acs.molpharmaceut.5b00162.CrossRefPubMedGoogle Scholar
  32. 32.
    Vellanki SRP, Sahu A, Katukuri AK, Vanama V, Kothari S, Ponnekanti S, et al. WO2011048604 (A2)-An improved process for the preparation of darunavir. Matrix Laboratories Limited 2011.Google Scholar
  33. 33.
    Acton QA. Therapy and treatment. In: Acton QA, editor. Virus diseases: new insights for the healthcare professional: 2013 Edition: ScholarlyEditions; 2013. p. 921–98.Google Scholar
  34. 34.
    Marom E. US2012035142 (A1)-Polymorphs of darunavir. MAPI PHARMA Ltd 2012.Google Scholar
  35. 35.
    Nageswara Rao R, Ramachandra B, Santhakumar K. RP-HPLC separation and characterization of unknown impurities of a novel HIV-protease inhibitor Darunavir by ESI-MS and 2D NMR spectroscopy. J Pharm Biomed Anal. 2013;75:186–91.  https://doi.org/10.1016/j.jpba.2012.10.022. CrossRefPubMedGoogle Scholar
  36. 36.
    Gottlieb HE, Kotlyar V, Nudelman A. NMR chemical shifts of common laboratory solvents as trace impurities. J Org Chem. 1997;62(21):7512–5.  https://doi.org/10.1021/jo971176v.CrossRefPubMedGoogle Scholar
  37. 37.
    Fulmer GR, Miller AJM, Sherden NH, Gottlieb HE, Nudelman A, Stoltz BM, et al. NMR chemical shifts of trace impurities: common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist. Organometallics. 2010;29(9):2176–9.  https://doi.org/10.1021/om100106e.CrossRefGoogle Scholar
  38. 38.
    Byrn SR, Zografi G, Chen X. X-ray Powder Diffraction. Solid State Properties of Pharmaceutical Materials: John Wiley & Sons, Inc.; 2017. p. 107–23.Google Scholar
  39. 39.
    Ferreira da Silva RM, Morais de Medeiros FP, Nascimento TG, Macêdo RO, Neto PJR. Thermal characterization of indinavir sulfate using TG, DSC and DSC-photovisual. J Therm Anal Calorim. 2009;95(3):965–8.  https://doi.org/10.1007/s10973-008-8912-7.CrossRefGoogle Scholar
  40. 40.
    Chadha R, Arora P, Saini A, Jain DS. Solvated crystalline forms of nevirapine: thermoanalytical and spectroscopic studies. AAPS PharmSciTech. 2010;11(3):1328–39.  https://doi.org/10.1208/s12249-010-9511-z.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Phull MS, Rao DR, Kankan RN. WO2011083287 (A2)-Darunavir polymorph and process for preparation thereof. Cipla Limited Curtis, Philip Anthony 2011.Google Scholar
  42. 42.
    Byrn S. Solid-state oxidation reactions. In: Byrn S, Pfeiffer R, Joseph S, editors. Solid-state chemistry of drugs. West Laffayette: IN: SSCI, Inc.; 1999. p. 279–303.Google Scholar
  43. 43.
    Byrn SR, Lin C-T. The effect of crystal packing and defects on desolvation of hydrate crystals of caffeine and L-(-)-1,4-cyclohexadiene-1-alanine. J Am Chem Soc. 1976;98(13):4004–5.  https://doi.org/10.1021/ja00429a048.CrossRefPubMedGoogle Scholar
  44. 44.
    Ressler C. Solid-state dehydrogenation of L-1,4-cyclohexadiene-1-alanine hydrate to L-phenylalanine. J Org Chem. 1972;37(19):2933–6.  https://doi.org/10.1021/jo00984a003.CrossRefPubMedGoogle Scholar
  45. 45.
    Rao RN, Ramachandra B, Sravan B, Khalid S. LC–MS/MS structural characterization of stress degradation products including the development of a stability indicating assay of darunavir: an anti-HIV drug. J Pharm Biomed Anal. 2014;89:28–33.  https://doi.org/10.1016/j.jpba.2013.10.007. CrossRefPubMedGoogle Scholar
  46. 46.
    Nie H, Liu Z, Marks BC, Taylor LS, Byrn SR, Marsac PJ. Analytical approaches to investigate salt disproportionation in tablet matrices by Raman spectroscopy and Raman mapping. J Pharm Biomed Anal. 2016;118:328–37.  https://doi.org/10.1016/j.jpba.2015.10.024. CrossRefPubMedGoogle Scholar
  47. 47.
    Nie H, Xu W, Ren J, Taylor LS, Marsac PJ, John CT, et al. Impact of metallic stearates on disproportionation of hydrochloride salts of weak bases in solid-state formulations. Mol Pharm. 2016;13(10):3541–52.  https://doi.org/10.1021/acs.molpharmaceut.6b00630.CrossRefPubMedGoogle Scholar
  48. 48.
    Nie H, Su Y, Zhang M, Song Y, Leone A, Taylor LS, et al. Solid-state spectroscopic investigation of molecular interactions between clofazimine and hypromellose phthalate in amorphous solid dispersions. Mol Pharm. 2016;13:3964–75.  https://doi.org/10.1021/acs.molpharmaceut.6b00740.CrossRefPubMedGoogle Scholar
  49. 49.
    Nie H, Xu W, Taylor LS, Marsac PJ, Byrn SR. Crystalline solid dispersion-a strategy to slowdown salt disproportionation in solid state formulations during storage and wet granulation. Int J Pharm. 2017;517(1):203–15.  https://doi.org/10.1016/j.ijpharm.2016.12.014. CrossRefPubMedGoogle Scholar
  50. 50.
    Law D, Krill SL, Schmitt EA, Fort JJ, Qiu Y, Wang W, et al. Physicochemical considerations in the preparation of amorphous ritonavir–poly(ethylene glycol) 8000 solid dispersions. J Pharm Sci. 2001;90(8):1015–25.  https://doi.org/10.1002/jps.1054. CrossRefPubMedGoogle Scholar
  51. 51.
    Nguyen DN, Van den Mooter G. The fate of ritonavir in the presence of darunavir. Int J Pharm. 2014;475(1):214–26.  https://doi.org/10.1016/j.ijpharm.2014.08.062. CrossRefPubMedGoogle Scholar
  52. 52.
    Calza L, Colangeli V, Magistrelli E, Bussini L, Conti M, Ramazzotti E, et al. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. HIV Med. 2017;18(7):474–81.  https://doi.org/10.1111/hiv.12478.CrossRefPubMedGoogle Scholar
  53. 53.
    FDA Reviewer Guidance: Validation of Chromatographic Methods. 5600 Fishers Lane, Rockville, MD 20857: FDA Office of Enforcement; 1994.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  1. 1.Department of Industrial and Physical PharmacyPurdue UniversityWest LafayetteUSA
  2. 2.Department of Medicinal Chemistry and Molecular PharmacologyPurdue UniversityWest LafayetteUSA

Personalised recommendations